WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2025

Hedge fundSEC filingsCompare with another fundHoldings as of 2025-12-31, filed 2026-02-13

Avidity Partners Management LP disclosed 39 US equity positions worth $346.7m in its Q4 2025 13F filing. Its largest position is DNTH at 25.0% of the reported book, followed by CGON and JBIO. Versus Q3 2025 it opened 11 new positions, added to 5, reduced 19 and exited 15.

$347m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
39
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
25.0%
Largest position
The largest single position as a share of the reported equity book.
71.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
9
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2025: 11 new, 5 added, 19 reduced, 15 exited

39 rows
DNTH DIANTHUS THERAPEUTICS INCHealthcare25.0%$86.7m2.10m−34%reduced
CGON CG ONCOLOGY INCHealthcare17.6%$61.1m1.47m−8.0%reduced
JBIO JADE BIOSCIENCES INCHealthcare6.2%$21.6m1.40m+24%added
ORKA ORUKA THERAPEUTICS INCHealthcare5.8%$20.0m660,4240.0%held
TEVA TEVA PHARMACEUTICAL INDS LTDHealthcare3.8%$13.0m417,300−18%reduced
BSX BOSTON SCIENTIFIC CORPHealthcare3.1%$10.9m114,500−30%reduced
MDT Medtronic PlcHealthcare3.0%$10.3m107,600−44%reduced
CATX PERSPECTIVE THERAPEUTICS INC–2.5%$8.8m3.21m+7.2%added
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare2.4%$8.4m21,000–new
RGEN REPLIGEN CORPHealthcare2.4%$8.2m50,300+116%added
CNTX CONTEXT THERAPEUTICS INC–2.3%$8.1m5.50m−39%reduced
MCK MCKESSON CORPHealthcare2.3%$7.8m9,520+64%added
ICLR ICON PLCHealthcare1.7%$6.0m33,100–new
A AGILENT TECHNOLOGIES INCHealthcare1.6%$5.6m41,500–new
PFE PFIZER INCHealthcare1.5%$5.1m203,600−44%reduced
CNC CENTENE CORP DELHealthcare1.4%$4.9m119,400–new
KVUE KENVUE INCConsumer Defensive1.2%$4.0m232,800−12%reduced
DHR DANAHER CORP DELHealthcare1.1%$3.9m17,000−69%reduced
TMO THERMO FISHER SCIENTIFIC INCHealthcare1.1%$3.9m6,700−65%reduced
NVO NOVO-NORDISK A SHealthcare1.0%$3.4m67,300–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.0%$3.4m206,076−33%reduced
EHC ENCOMPASS HEALTH CORPHealthcare1.0%$3.4m31,600−25%reduced
CI THE CIGNA GROUPHealthcare0.9%$3.2m11,600−30%reduced
COR CENCORA INCHealthcare0.9%$3.2m9,400−51%reduced
INSM INSMED INCHealthcare0.9%$3.1m17,700+53%added
WAT WATERS CORPHealthcare0.9%$3.1m8,100–new
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.8%$2.9m106,900−26%reduced
GMAB GENMAB A/SHealthcare0.8%$2.8m92,000−63%reduced
NTRA NATERA INCHealthcare0.8%$2.7m11,800−83%reduced
IMUX IMMUNIC INCHealthcare0.7%$2.5m4.70m0.0%held
ACHC ACADIA HEALTHCARE COMPANY INHealthcare0.7%$2.4m169,000–new
ITGR INTEGER HLDGS CORPHealthcare0.7%$2.3m29,800–new
ELVN ENLIVEN THERAPEUTICS INCHealthcare0.6%$2.2m140,3000.0%held
PVLA PALVELLA THERAPEUTICS INC NEHealthcare0.6%$2.0m19,300–new
HQY HEALTHEQUITY INCHealthcare0.4%$1.5m16,900−33%reduced
SCYX SCYNEXIS INC–0.4%$1.3m2.08m−38%reduced
IQV IQVIA HLDGS INCHealthcare0.3%$992k4,400–new
KPTI KARYOPHARM THERAPEUTICS INC–0.3%$990k134,5660.0%held
CORT CORCEPT THERAPEUTICS INCHealthcare0.2%$766k22,000–new

Exited since Q3 2025

15 rows
BMY BRISTOL-MYERS SQUIBB CO2.6%$11.6m
METSERA INC no ticker1.7%$7.4m
UNH UNITEDHEALTH GROUP INC1.4%$6.1m
ARVN ARVINAS INC1.4%$6.0m
JNJ JOHNSON & JOHNSON1.1%$5.0m
ABBV ABBVIE INC1.0%$4.6m
CARL CARLSMED INC1.0%$4.3m
ARQT ARCUTIS BIOTHERAPEUTICS INC0.9%$4.0m
EXK EXACT SCIENCES CORP0.9%$4.0m
ASND ASCENDIS PHARMA A/S0.7%$2.9m
BEAM BEAM THERAPEUTICS INC0.6%$2.7m
WVE WAVE LIFE SCIENCES LTD0.5%$2.2m
XENE XENON PHARMACEUTICALS INC0.5%$2.1m
AKROEUR AKERO THERAPEUTICS INC0.4%$1.9m
IMRX IMMUNEERING CORP0.1%$636k

Sector mix

  • Healthcare93.3%
  • Unclassified5.5%
  • Consumer Defensive1.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters